- Conditions
- Hepatocellular Carcinoma
- Interventions
- Cabozantinib, Sorafenib, Atezolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 26 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 13,967
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain
- Interventions
- Conventional root canal treatment, Ultrasonic, Apical negative pressure, Combined Ultrasonic and negative pressure
- Device
- Lead sponsor
- Cleveland Dental Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
- Interventions
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
- Other · Genetic · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Acute Heart Failure
- Interventions
- sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 887 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
- Conditions
- Essential Hypertension
- Interventions
- XOMA 985, Amlodipine Besylate, Perindopril Erbumine
- Drug
- Lead sponsor
- Symplmed Pharmaceuticals LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 837 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Muscle Shoals, Alabama • Glendale, Arizona + 45 more
- Conditions
- Breast Cancer
- Interventions
- Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions), Letrozole 2.5Mg Tab, Palbociclib 125mg
- Radiation · Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Aging
- Interventions
- Tai Chi, Guided autobiography, Qigong, Successful aging, Combination, Comparison
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Interventions
- AZD8931, anastrozole, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 482 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Hypertension, Blood Pressure, High
- Interventions
- Ramipril and hydrochlorothiazide
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
- Conditions
- Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
- Interventions
- an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers
- Drug · Other
- Lead sponsor
- Ayu, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Trimethoprim, Sulfamethoxazole, Dapsone, Leucovorin calcium
- Drug
- Lead sponsor
- U.S. Bioscience
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Drug Interactions, Drug Kinetics
- Interventions
- Alprazolam, Oxycodone, Placebo
- Drug
- Lead sponsor
- Shanna Babalonis, PhD
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Myeloproliferative Diseases
- Interventions
- Ruxolitinib, Lenalidomide, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, Metformin Hydrochloride
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma
- Interventions
- rituximab, methotrexate, temozolomide 100 mg/m^2, temozolomide 150 mg/m^2, temozolomide 200 mg/m^2, radiation therapy, post-radiation therapy temozolomide
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 26
- States / cities
- Jacksonville, Florida • Jacksonville Beach, Florida • Orange Park, Florida + 17 more
- Conditions
- Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer
- Interventions
- mitomycin C, oxaliplatin, therapeutic conventional surgery, quality-of-life assessment, hyperthermic intraperitoneal chemotherapy
- Drug · Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 3
- States / cities
- Winston-Salem, North Carolina • Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Glioblastoma
- Interventions
- Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed, Renal Cell Carcinoma (RCC) (Phase ll Only), Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed
- Interventions
- Combination of varlilumab and nivolumab
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more
- Conditions
- CoronaVirus Disease-2019 (COVID-19)
- Interventions
- ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
- Conditions
- Anal Cancer
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Irritable Bowel Syndrome
- Interventions
- Diet A - elimination diet, Diet B - healthy eating diet
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pancreas Cancer
- Interventions
- GI-4000, Gemcitabine
- Biological · Drug
- Lead sponsor
- GlobeImmune
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 14 more
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Interventions
- oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 9
- States / cities
- Fairfield, Connecticut • Guilford, Connecticut • Hartford, Connecticut + 6 more
- Conditions
- Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Interventions
- Cytarabine, Decitabine, Idarubicin, Laboratory Biomarker Analysis, Liposome-encapsulated Daunorubicin-Cytarabine, Quality-of-Life Assessment, Questionnaire Administration, Azacitidine, Venetoclax, glasdegib
- Drug · Other
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska